Sandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 54,244 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the transaction, the chief accounting officer now owns 54,410 shares in the company, valued at approximately $1,360,250. The trade was a 49.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Monday, February 3rd, Sandra Calvin sold 3,348 shares of Travere Therapeutics stock. The stock was sold at an average price of $20.12, for a total value of $67,361.76.
• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.94, for a total value of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Stock Down 2.3 %

Shares of NASDAQ:TVTX opened at $23.20 on Thursday. The business has a fifty day moving average of $19.06 and a 200-day moving average of $15.95. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Emerald Advisers LLC grew its stake in shares of Travere Therapeutics by 8.4% during the fourth quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company’s stock valued at $37,030,000 after purchasing an additional 165,085 shares during the last quarter. Geode Capital Management LLC boosted its position in Travere Therapeutics by 6.4% in the 4th quarter. Geode Capital Management LLC now owns 1,842,301 shares of the company’s stock valued at $32,100,000 after buying an additional 111,256 shares during the last quarter. Finepoint Capital LP increased its stake in shares of Travere Therapeutics by 0.3% in the 3rd quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock valued at $24,934,000 after buying an additional 5,539 shares during the period. Emerald Mutual Fund Advisers Trust increased its stake in shares of Travere Therapeutics by 26.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock valued at $16,588,000 after buying an additional 244,444 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in shares of Travere Therapeutics by 12.0% during the third quarter. Parkman Healthcare Partners LLC now owns 1,086,067 shares of the company’s stock worth $15,194,000 after acquiring an additional 116,175 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TVTX. Scotiabank boosted their price target on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday. Barclays upped their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Piper Sandler raised their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. Cantor Fitzgerald initiated coverage on Travere Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating on the stock. Finally, HC Wainwright raised their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.77.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.